South Korea · Delayed Price · Currency is KRW S.Biomedics Company Description
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products.
Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration; CF-TED-N for the treatment of stroke; and CF-FECS-DF for the treatment of wound.
The company provides testing services; and owns platform technologies for developing cell therapy products.
The company has a strategic partnership with Catalent, Inc. for the development and manufacturing of TED-A9.
S.Biomedics CO., LTD. was founded in 2005 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 2005 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Dong-Wook Kim |
Contact Details
Address: Wooil Venture Town Building Seoul South Korea | |
| Phone | 82 2 2205 0023 |
| Website | sbiomedics.com |
Stock Details
| Ticker Symbol | 304360 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dong-Wook Kim | Chief Executive Officer |